| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRNEUROL.2012.111 |
| P698 | PubMed publication ID | 22664785 |
| P50 | author | Santiago Perez-Lloret | Q67389929 |
| Olivier Rascol | Q28359611 | ||
| P2860 | cites work | Depression in Parkinson disease--epidemiology, mechanisms and management. | Q37971293 |
| Blinding in randomised trials: hiding who got what. | Q52937785 | ||
| Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials | Q27691373 | ||
| A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. | Q30419918 | ||
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease | Q33607256 | ||
| Depression rating scales in Parkinson's disease: critique and recommendations | Q34578187 | ||
| Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial | Q34619438 | ||
| A controlled trial of antidepressants in patients with Parkinson disease and depression | Q37180389 | ||
| Selegiline transdermal system: a novel treatment option for major depressive disorder | Q37519729 | ||
| Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France | Q37889802 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 365-366 | |
| P577 | publication date | 2012-06-05 | |
| P1433 | published in | Nature Reviews Neurology | Q2079285 |
| P1476 | title | Parkinson disease: Serotonin reuptake inhibitors for depression in PD. | |
| P478 | volume | 8 |
| Q34242604 | Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease |
| Q35158376 | Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? |
| Q47557364 | LRRK2 G2019S induces anxiety/depression-like behavior prior to the onset of motor dysfunction with 5-HT1A receptor upregulation in mice |
| Q48290666 | Methylphenidate : a treatment for Parkinson's disease? |
| Q33826463 | Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease |
| Q35165280 | Monoamine reuptake inhibitors in Parkinson's disease |
| Q64972290 | The pharmacologic management of depression in Parkinson's disease. |
Search more.